sm-130686 has been researched along with Weight-Gain* in 2 studies
2 other study(ies) available for sm-130686 and Weight-Gain
Article | Year |
---|---|
Structure-activity relationships of the oxindole growth hormone secretagogues.
A series of substituted oxindole derivatives of SM-130686 was synthesized and evaluated as ghrelin receptor agonists. Modification of the substituents on the C3-aromatic part of the oxindole led to compounds with subnanomolar binding affinities. Compound 4i (IC(50)=0.02 nM) was orally active at low doses and showed in vivo activity when orally administered, 2 mg/kg twice a day for 4 days, as evidenced by significant body weight gain. Topics: Administration, Oral; Animals; Ethylamines; Growth Hormone; Indoles; Inhibitory Concentration 50; Rats; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Ghrelin; Structure-Activity Relationship; Time Factors; Weight Gain | 2005 |
Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686.
SM-130686, an oxindole derivative, is a novel orally active GH secretagogue (GHS) which is structurally distinct from previously reported GHSs such as MK-677, NN703 and hexarelin. SM-130686 stimulates GH release from cultured rat pituitary cells in a dose-dependent manner. Half-maximum stimulation was observed at a concentration of 6.3+/-3.4 nM. SM-130686-induced GH release was inhibited by a GHS antagonist, but not by a GH-releasing hormone antagonist. SM-130686 dose-dependently inhibited the binding of radiolabeled ligand, (35)S-MK-677, to human GHS receptor 1a (IC(50)=1.2 nM). This indicates that SM-130686 stimulates GH release through the GHS receptor. The effect of a single oral administration of SM-130686 on GH release in pentobarbital-anesthetized rats was studied. After treatment with 10 mg/kg SM-130686, plasma GH concentrations measured by radioimmunoassay significantly increased, reaching a peak at 20-45 min, and remained above baseline during the experimental period (60 min). The anabolic effect of repetitive SM-130686 administration was studied in rats. Rats received 10 mg/kg SM-130686 orally twice a day and were weighed every day for 9 days. At day 9 there was a significant increase in both the body weight and the fat free mass (19.5+/-2.1 and 18.1+/-7.5 g respectively). Serum IGF-I concentration was also significantly elevated 6 h after the last dose of SM-130686. An endogenous GHS ligand for the GHS receptor has recently been identified from stomach extract and designated as ghrelin. The GH-releasing activity in vitro relative to ghrelin (100%) was about 52% for SM-130686. It is likely that SM-130686 is a partial agonist for the GHS receptor. In summary, we describe here an orally active GHS, SM-130686, which acts through the GHS receptor. Repetitive administration of SM-130686 to rats, similar to repetitive administration of GH, significantly increased the fat free mass by an amount almost equal to the gain in body weight. Topics: Administration, Oral; Animals; Cell Culture Techniques; Dose-Response Relationship, Drug; Drug Administration Schedule; Ethylamines; Female; Ghrelin; Growth Hormone; Growth Hormone-Releasing Hormone; Indoles; Male; Peptide Hormones; Peptides; Pituitary Gland, Anterior; Rats; Rats, Inbred F344; Rats, Wistar; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Ghrelin; Weight Gain | 2001 |